BNP Paribas Financial Markets Sells 39,697 Shares of Globus Medical, Inc. $GMED

BNP Paribas Financial Markets reduced its stake in Globus Medical, Inc. (NYSE:GMED) by 18.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 177,736 shares of the medical device company’s stock after selling 39,697 shares during the quarter. BNP Paribas Financial Markets’ holdings in Globus Medical were worth $15,518,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. AQR Capital Management LLC raised its stake in Globus Medical by 45.9% in the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock valued at $1,622,000 after acquiring an additional 7,086 shares during the period. Integrated Wealth Concepts LLC raised its holdings in Globus Medical by 33.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after acquiring an additional 1,085 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Globus Medical by 38.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after acquiring an additional 8,540 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Globus Medical by 237.3% in the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after purchasing an additional 598 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after buying an additional 28,027 shares during the period. Institutional investors own 95.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on GMED. Barclays raised their price target on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wells Fargo & Company lowered their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Needham & Company LLC increased their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Royal Bank Of Canada raised their price objective on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Trading Up 0.2%

Shares of GMED opened at $80.13 on Friday. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The firm’s 50-day moving average price is $86.27 and its 200-day moving average price is $88.21. The firm has a market capitalization of $10.88 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 1.65 and a beta of 0.95.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.